Clinical trials: Pancreatic Cancer Stage I
Pancreatic Carcinoma, Tumors That Express CA 19-9
Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
Open label, nonrandomized, dose-escalation with cohort expansion study of MVT-5873/MVT-1075 in subjects with previously treated, Carbohydrate Antigen 19-9 (CA19-9) positive malignancies (e.g., pancreatic adenocarcinoma).
- Trial name
- NCT03118349
- Testing
- MVT-1075, MVT-5873
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- BioNTech Research & Development, Inc.
Pancreatic Neoplasms
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of pancreatic cancer.
- Trial name
- NCT00041639
- Testing
- hMN14 (labetuzumab)
- Where
- 10 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- Gilead Sciences
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01234935
- Testing
- dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- 17 sites in United States
- Volunteers
- 8 people
- Sponsor
- Translational Oncology Research International
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma, Pancreatic Neoplasms
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
This phase I trial studies the side effects and the best dose of MLN8237 (alisertib) when given together with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with solid malignancies…
- Trial name
- NCT01677559
- Testing
- MLN8237, nab-Paclitaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
This randomized phase I trial studies how well anti-semaphorin 4D (anti-SEMA4D) monoclonal antibody VX15/2503 with or without ipilimumab or nivolumab work in treating patients with stage I-III pancreatic cancer that can be…
- Conditions
- Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
- Trial name
- NCT03373188
- Testing
- Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Emory University
Pancreatic Neoplasms
SBRT Pre-operatively for Pancreatic Cancer
In this study the investigators are testing if the addition of Stereotactic Body Radiation therapy (SBRT) prior to surgery improves surgical outcome in patients with borderline resectable or resectable pancreatic cancer (BRPC).
- Trial name
- SPARC (NCT02308722)
- Testing
- 5-fraction stereotactic body radiation therapy
- Where
- 5 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
This phase I trial studies the side effects and best dose of anetumab ravtansine when given together with nivolumab, ipilimumab and gemcitabine hydrochloride in treating patients with mesothelin positive pancreatic cancer that…
- Conditions
- Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT03816358
- Testing
- Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection
- Where
- 45 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Pancreatic Cancer
A Study of Irinotecan Liposome in Advanced Pancreatic Cancer
To determine the safety and tolerability of irinotecan liposome in combination with oxaliplatin and 5-FU/LV in subjects with advanced pancreatic cancer who have not received prior systemic chemotherapy
- Trial name
- NCT04796948
- Testing
- Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Pancreatic Cancer
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer.
- Trial name
- NCT00003025
- Testing
- vitespen
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Pancreatic Cancer
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with with advanced pancreatic cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended…
- Trial name
- NCT04928625
- Testing
- SHR-A1904
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Pancreatic Neoplasms
Trial of Neoadjuvant Short Course IMRT Followed by Surgery and IORT for Resectable Pancreatic Cancer
The current standard treatment for patients with primarily resectable pancreatic tumors consists of surgery followed by adjuvant chemotherapy.
- Trial name
- NEOPANC (NCT01372735)
- Testing
- neoadjuvant short course IMRT, IORT
- Where
- 3 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Heidelberg
Metastatic Pancreatic Cancer
Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
Eligible candidates will be adults with metastatic pancreatic cancer (confirmed diagnosis with pathology reports and measurable computed tomography (CT) or magnetic resonance imaging (MRI)).
- Trial name
- NCT00954525
- Testing
- Gemcitabine and Erlotinib, Intravenous Vitamin C
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Pancreatic Neoplasms
Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
This is a phase 1 (first in man) study testing the safety of adding high dose ascorbate (vitamin C) to standard radiation and chemotherapy for treatment of pancreatic cancer.
- Trial name
- NCT01852890
- Testing
- Ascorbate, Gemcitabine, Radiation therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Joseph J. Cullen
Pancreatic Cancer, Gastric Cancer
Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
This study is for people with advanced cancer of the digestive tract and cancer that cannot be completely removed by surgery. Radiation therapy is commonly used in the treatment of these types of cancer in combination with a…
- Conditions
- Pancreatic Cancer, Gastric Cancer, Duodenum Cancer, Bile Duct Cancer
- Trial name
- NCT00183846
- Testing
- irinotecan, radiation therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Southern California
Pancreatic Cancer
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2*…
- Trial name
- NCT06129422
- Testing
- NMK89
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Nihon Medi-Physics Co., Ltd.
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen